Compare VanEck Gold Miners ETF (GDX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs State Street SPDR S&P Biotech ETF — how do they compare? VanEck Gold Miners ETF trades at $71.52, while State Street SPDR S&P Biotech ETF trades at $152. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| GDX | XBI | |
|---|---|---|
52-Week High | $115.84 | $164.28 |
52-Week Low | $51.15 | $85.16 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX (VanEck Gold Miners ETF) trades at $71.42, down 4.62% with bearish technical signals from moving averages. The fund faces competition from lower-fee gold ETFs while offering mining equity exposure with higher volatility. Recent portfolio changes include the addition of Aya Gold & Silver, potentially enhancing diversification. Technical indicators show neutral oscillators but overall bearish momentum with key support at $70.
The outlook remains cautious as gold miners navigate gold price volatility and fee competition. Upside potential exists if gold rebounds, but investors face risks from sector underperformance relative to physical gold. Analyst views are mixed, with some seeing value in discounted valuations while others highlight structural challenges in the mining ETF space.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
